vs
Side-by-side financial comparison of RHYTHM PHARMACEUTICALS, INC. (RYTM) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). Viridian Therapeutics, Inc.\DE runs the higher net margin — -49.0% vs -83.0%, a 33.9% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 36.9%).
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
RYTM vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.3M | $70.6M |
| Net Profit | $-47.5M | $-34.6M |
| Gross Margin | 91.6% | — |
| Operating Margin | -82.2% | -56.7% |
| Net Margin | -83.0% | -49.0% |
| Revenue YoY | 36.9% | 81958.1% |
| Net Profit YoY | -9.6% | 54.9% |
| EPS (diluted) | $-0.73 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.3M | — | ||
| Q3 25 | $51.3M | $70.6M | ||
| Q2 25 | $48.5M | — | ||
| Q1 25 | $32.7M | — | ||
| Q4 24 | $41.8M | — | ||
| Q3 24 | $33.3M | — | ||
| Q2 24 | $29.1M | — | ||
| Q1 24 | $26.0M | — |
| Q4 25 | $-47.5M | — | ||
| Q3 25 | $-52.9M | $-34.6M | ||
| Q2 25 | $-46.6M | — | ||
| Q1 25 | $-49.5M | — | ||
| Q4 24 | $-43.3M | — | ||
| Q3 24 | $-43.6M | — | ||
| Q2 24 | $-32.3M | — | ||
| Q1 24 | $-141.4M | — |
| Q4 25 | 91.6% | — | ||
| Q3 25 | 89.3% | — | ||
| Q2 25 | 88.6% | — | ||
| Q1 25 | 88.8% | — | ||
| Q4 24 | 90.9% | — | ||
| Q3 24 | 88.5% | — | ||
| Q2 24 | 89.9% | — | ||
| Q1 24 | 89.2% | — |
| Q4 25 | -82.2% | — | ||
| Q3 25 | -102.6% | -56.7% | ||
| Q2 25 | -93.4% | — | ||
| Q1 25 | -143.7% | — | ||
| Q4 24 | -98.6% | — | ||
| Q3 24 | -132.0% | — | ||
| Q2 24 | -139.2% | — | ||
| Q1 24 | -538.7% | — |
| Q4 25 | -83.0% | — | ||
| Q3 25 | -103.1% | -49.0% | ||
| Q2 25 | -96.1% | — | ||
| Q1 25 | -151.4% | — | ||
| Q4 24 | -103.6% | — | ||
| Q3 24 | -131.2% | — | ||
| Q2 24 | -110.9% | — | ||
| Q1 24 | -544.4% | — |
| Q4 25 | $-0.73 | — | ||
| Q3 25 | $-0.82 | — | ||
| Q2 25 | $-0.75 | — | ||
| Q1 25 | $-0.81 | — | ||
| Q4 24 | $-0.71 | — | ||
| Q3 24 | $-0.73 | — | ||
| Q2 24 | $-0.55 | — | ||
| Q1 24 | $-2.35 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $388.9M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.1M | $503.0M |
| Total Assets | $480.2M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.9M | — | ||
| Q3 25 | $416.1M | $490.9M | ||
| Q2 25 | $291.0M | — | ||
| Q1 25 | $314.5M | — | ||
| Q4 24 | $320.6M | — | ||
| Q3 24 | $298.4M | — | ||
| Q2 24 | $319.1M | — | ||
| Q1 24 | $201.2M | — |
| Q4 25 | $139.1M | — | ||
| Q3 25 | $148.8M | $503.0M | ||
| Q2 25 | $-11.9M | — | ||
| Q1 25 | $18.9M | — | ||
| Q4 24 | $21.7M | — | ||
| Q3 24 | $11.2M | — | ||
| Q2 24 | $39.3M | — | ||
| Q1 24 | $61.6M | — |
| Q4 25 | $480.2M | — | ||
| Q3 25 | $506.9M | $577.1M | ||
| Q2 25 | $372.7M | — | ||
| Q1 25 | $386.7M | — | ||
| Q4 24 | $392.3M | — | ||
| Q3 24 | $363.6M | — | ||
| Q2 24 | $381.8M | — | ||
| Q1 24 | $258.7M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-25.4M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-25.4M | — | ||
| Q3 25 | $-26.6M | $-84.6M | ||
| Q2 25 | $-23.3M | — | ||
| Q1 25 | $-40.4M | — | ||
| Q4 24 | $-18.8M | — | ||
| Q3 24 | $-25.2M | — | ||
| Q2 24 | $-29.1M | — | ||
| Q1 24 | $-40.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
